HK Stock Market Move | AKESO (09926) rose over 5% in early trading. The first patient enrolled in the Phase III clinical study of pancreatic cancer treated with Ivos therapy.

AKESO (09926) rose more than 5% in the morning session, as of the time of writing, it rose 3.84% to HK$148.9, with a turnover of HK$525 million. On the news front, AKESO announced that its self-developed global pioneering PD-1/VEGF bispecific antibody new drug Yivosi (trade name: Idafan) in combination with chemotherapy combined/uncombined with Lefarmil (CD47 monoclonal antibody) for the key/registration Phase III study of first-line metastatic pancreatic cancer (AK112-310/HARMONi-GI2) has completed the enrollment of the first patient. Yivosi in combination with chemotherapy combined/uncombined with Lefarmil is expected to fill the gap in first-line immunotherapy for the treatment of metastatic pancreatic cancer. Of note, on July 16, the company's official website announced that its global dual-targeted Yivosi monoantibody for the first-line treatment of late-stage pMMR/MSS (mismatch repair function intact/microsatellite stable) mCRC (metastatic colorectal cancer) has completed the enrollment of the first patient in the registration Phase 3 clinical trial (AK112-312/HARMONi-GI6). Sinolink pointed out that Kadenili and Yivosi are expected to be included in the national medical insurance in 2024, and are expected to bring accelerated sales revenue from 2025 onwards. Yivosi has been approved for use in 18 indications through combination, with more than 27 clinical trials conducted, including 12 Phase 3 trials and 7 head-to-head studies; Kadenili has been used in 20 indications and has conducted 28 clinical trials.